Breast cancer treatment Ibrance has added safety-related product information in male patients. The Ministry of Food and Drug Safety recently added a phrase that male patients also showed consistent safety profiles with women in post-marketing experience through updating the permits of CDK4/6 inhibitor Ibrance of Pfizer Korea. The measure was based on the results of post-marketing surveys and electronic health records in the United States, and the U.S. FDA expanded its indication to prescribe Ibrance to male patients based on the data in 2019.

Male breast cancer is a rare disease that accounts for about 1% of all breast cancers, and most of the patients' mammary tumors are expressed in hormone receptors